EUVIMEDEUVIMED entdecken
Crossref

A bis-boron boramino acid PET tracer for brain tumor diagnosis

Zhu Li, Junyi Chen, Ziren Kong, Yixin Shi, Mengxin Xu, Bo-Shuai Mu, Nan Li, Wenbin Ma, Zhi Yang, Yu Wang, Zhibo Liu iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06600-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Zhu Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, …. Hauptthemen laut MEDLINE: Boron Compounds, Brain Neoplasms, Fluorine Radioisotopes, Phenylalanine. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Boramino acids are a class of amino acid biomimics that replace the carboxylate group with trifluoroborate and can achieve the 18F-labeled positron emission tomography (PET) and boron neutron capture therapy (BNCT) with identical chemical structure. METHODS: This study reports a trifluoroborate-derived boronophenylalanine (BBPA), a derived boronophenylalanine (BPA) for BNCT, as a promising PET tracer for tumor imaging. RESULTS: Competition inhibition assays in cancer cells suggested the cell accumulation of [18F]BBPA is through large neutral amino acid transporter type-1 (LAT-1). Of note, [18F]BBPA is a pan-cancer probe that shows notable tumor uptake in B16-F10 tumor-bearing mice. In the patients with gliomas and metastatic brain tumors, [18F]BBPA-PET shows good tumor uptake and notable tumor-to-normal brain ratio (T/N ratio, 18.7 ± 5.5, n = 11), higher than common amino acid PET tracers. The [18F]BBPA-PET quantitative parameters exhibited no difference in diverse contrast-enhanced status (P = 0.115-0.687) suggesting the [18F]BBPA uptake was independent from MRI contrast-enhancement. CONCLUSION: This study outlines a clinical trial with [18F]BBPA to achieve higher tumor-specific accumulation for PET, provides a potential technique for brain tumor diagnosis, and might facilitate the BNCT of brain tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Boron CompoundsBrain NeoplasmsFluorine RadioisotopesPhenylalaninePositron Emission Tomography Computed TomographyRadioactive TracersAnimalsFemaleHumansMiceBoron Neutron Capture TherapyBrainHealthy VolunteersLarge Neutral Amino Acid-Transporter 1Magnetic Resonance ImagingMelanoma, ExperimentalMice, Inbred C57BLMolecular ProbesXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Boramino acidBrain tumorPositron emission tomography

Substanzen

4-boronophenylalanineBoron CompoundsFluorine RadioisotopesLarge Neutral Amino Acid-Transporter 1Molecular ProbesPhenylalanineRadioactive Tracers

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China.
  • Beijing National Laboratory for Molecular Sciences, Radiochemistry and Radiation Chemistry Key Laboratory of Fundamental Science, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education…
  • Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Head and Neck Surgery, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. ywang@pumch.cn.
  • Key Laboratory of Carcinogenesis and Translational Research, Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, China. zbliu@pku.edu.cn.

ORCID-Profile: Zhibo Liu

Förderung

  • Natural Science Foundation of Beijing Municipality
  • National Natural Science Foundation of China
  • Ministry of Science and Technology of the People's Republic of China
  • Changping Laboratory
  • Science Foundation of Peking University Cancer Hospital
  • Special Research Fund for Central Universities, and Peking Union Medical College
  • National High Level Hospital Clinical Research Funding
  • Ministry of Science and Technology of the People’s Republic of China

Zitieren

APA

Li, Z., Chen, J., Kong, Z., Shi, Y., Xu, M., Mu, B. S., Li, N., Ma, W., Yang, Z., Wang, Y., & Liu, Z. (2024). A bis-boron boramino acid PET tracer for brain tumor diagnosis. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06600-5

Vancouver

Li Z, Chen J, Kong Z, Shi Y, Xu M, Mu BS, et al. A bis-boron boramino acid PET tracer for brain tumor diagnosis. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06600-5

BibTeX
@article{Li2024,
  author = {Li, Zhu and Chen, Junyi and Kong, Ziren and Shi, Yixin and Xu, Mengxin and Mu, Bo-Shuai and Li, Nan and Ma, Wenbin and Yang, Zhi and Wang, Yu and Liu, Zhibo},
  title = {A bis-boron boramino acid PET tracer for brain tumor diagnosis},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06600-5}
}
Kostenlos starten →